MOTS-C (10mg)

MOTS-C (10mg) protocols focus on this mitochondria-derived peptide studied for its potential role in regulating metabolic homeostasis, insulin sensitivity, and cellular energy balance. MOTS-C is believed to support improved glucose utilization, fat metabolism, and exercise performance by acting directly on mitochondrial signaling pathways. This guide outlines a subcutaneous administration approach optimized for the 10 mg vial format.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical daily range: 2.5–10 mg (subcutaneous, depending on protocol design)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks

Concise summary of the subcutaneous regimen.

  • Goal: Support metabolic flexibility, insulin sensitivity, and energy regulation
  • Schedule: Daily or cyclic subcutaneous injections depending on protocol
  • Dose Range: 2.5–10 mg per day (or cycle-based use in some protocols)

Suggested approach for the 10 mg vial format.

  • Start: 2.5 mg once daily to assess response
  • Target: 5–10 mg per day, depending on goals and tolerance
  • Frequency: Once daily or split dosing (AM/PM) in higher protocols
  • Vial Duration: One 10 mg vial lasts 1–4 days, depending on dose
  • Timing: Morning use is often preferred for metabolic and activity support

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA type-C) is a mitochondria-encoded peptide involved in regulating cellular metabolism. Unlike nuclear-encoded peptides, MOTS-C originates from mitochondrial DNA and acts as a signaling molecule that influences energy homeostasis.

Research suggests MOTS-C may activate metabolic pathways such as AMPK, which plays a key role in glucose uptake, fatty acid oxidation, and mitochondrial efficiency. It may also enhance the body’s ability to adapt to metabolic stress, improving insulin sensitivity and supporting energy utilization in skeletal muscle.

Preclinical studies indicate MOTS-C may improve exercise capacity, protect against diet-induced obesity, and support metabolic health under conditions of aging or metabolic dysfunction.

Observations based on preclinical and early research.

Potential Benefits:

  • May improve insulin sensitivity and glucose metabolism
  • May support fat oxidation and metabolic flexibility
  • May enhance exercise endurance and performance
  • May support cellular energy balance and mitochondrial function

Possible Side Effects:

  • Mild fatigue or headache in some users
  • Temporary injection-site irritation
  • Limited long-term human safety data available
  • Remains investigational with primarily preclinical evidence